Request Trial
shuterstock-138839393
Lightspring / Shutterstock.com
27 November 2014Ranjna Mehta-Dutt and Neha Srivastava

Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
Leading European patent litigator to join Carpmaels & Ransford
18 September 2026   The new hire brings more than two decades’ experience managing complex cross-border disputes in life sciences and technology, including most recently at the Unified Patent Court.
In-house counsel
CIPA Congress: Sustainability is essential for the profession and the planet
18 September 2026   At an event attended by patent experts and judges from Europe, the US and China, delegates gathered in the innovation hub of Manchester, UK, to debate the theme of sustainability "in its broadest sense". Sarah Speight was there to hear ideas spanning the commercialisation of clean tech, to ensuring the patent profession’s resilience in a time of colossal change.
Pharma
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

Beyond the primary patent: How pharma can build competitive barriers
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
The UPC plugs another gap in its procedural rulebook
Trump slaps 100% tariff on generic drugs in US manufacturing push
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
‘Blatant imitation’: Indian court blocks copycat pharma branding
US life sciences damages averaged $33.5m between 2019-2025
Chadha & Chadha hires former Remfry & Sagar patent partner